| __timestamp | Corcept Therapeutics Incorporated | Grifols, S.A. |
|---|---|---|
| Wednesday, January 1, 2014 | 34916000 | 660772000 |
| Thursday, January 1, 2015 | 36949000 | 736435000 |
| Friday, January 1, 2016 | 45240000 | 775266000 |
| Sunday, January 1, 2017 | 62416000 | 860348000 |
| Monday, January 1, 2018 | 81289000 | 814775000 |
| Tuesday, January 1, 2019 | 100359000 | 942821000 |
| Wednesday, January 1, 2020 | 105326000 | 985616000 |
| Friday, January 1, 2021 | 122356000 | 1061508000 |
| Saturday, January 1, 2022 | 152848000 | 1190423000 |
| Sunday, January 1, 2023 | 184259000 | 1254234000 |
Cracking the code
In the ever-evolving pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Grifols, S.A. and Corcept Therapeutics Incorporated from 2014 to 2023. Over this period, Grifols, S.A. consistently outpaced Corcept Therapeutics in SG&A spending, reflecting its expansive global operations. By 2023, Grifols' SG&A expenses surged by approximately 90% from 2014, reaching over €1.25 billion. In contrast, Corcept Therapeutics exhibited a more dramatic growth trajectory, with a staggering 428% increase, culminating in nearly €184 million in 2023. This disparity highlights Grifols' established market presence and Corcept's aggressive growth strategy. As the pharmaceutical landscape continues to shift, these trends offer valuable insights into the strategic priorities of these industry leaders.
AstraZeneca PLC and Grifols, S.A.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated Trends and Insights
Alnylam Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated: SG&A Expense Trends
Insmed Incorporated and Corcept Therapeutics Incorporated: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Bio-Techne Corporation and Grifols, S.A.
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Axsome Therapeutics, Inc.
Breaking Down SG&A Expenses: Grifols, S.A. vs Amphastar Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Rhythm Pharmaceuticals, Inc.
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs ACADIA Pharmaceuticals Inc. Trends and Insights
Corcept Therapeutics Incorporated vs Bausch Health Companies Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc. Trends and Insights